•Q4 operating cash inflow was $1.4m up 481% on same quarter prior year
• Revenue of $1.43 million, an increase of 12% on the March 2017 quarter ($1.27m) and 367% ahead of the June 2016 quarter
• FY17 total operating cash inflow was $5.02m ($5.5m including R&D Rebate) and FY17 Operating revenue totalled $4.24m (excludes R&D Rebate), 210% higher than FY16
• Positive operational performance and growth across key metrics: o Over 830,000 users on the MedAdvisor platform, an increase of 17% on the March 2017 quarter o Expanded the MedAdvisor Pharmacy Network, to over 2,600+, with MedAdvisor now providing its platform to all of Discount Drug Stores (DDS) nationwide
• Dr David Chatterton (ex Aconex Ltd CTO – ASX:ACX) appointed Chief Technology Officer ahead of next phase of growth • New pharmacy software platform developed “PlusOne” that will provide additional pharmacy services and expand revenue opportunities for MedAdvisor and network pharmacy customers
Ann: MDR Jun-17 Quarterly Report & 4C, page-2
Add MDR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
-0.005(1.23%) |
Mkt cap ! $220.5M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 41.5¢ | 40.0¢ | $43.65K | 108.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 46211 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 16830 | 1 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| MDR (ASX) Chart |